CIK 0001396814 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Revenue (USD) | 726.4 M | 666.8 M | ||
| Net income (USD) | 145.5 M | |||
| Diluted EPS (USD/shares) | 0.16 | 0.34 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-13 | SCHEDULE 13D/A | SCHEDULE 13D/A | |
| 2026-10-09 | 4 | FORM 4 | 2026-10-08 |
| 2026-10-08 | SC TO-C | SC TO-C | |
| 2026-10-08 | SC14D9C | SC14D9C | |
| 2026-10-08 | 144 | 144 | |
| 2026-10-08 | 8-K | FORM 8-K items 1.01,7.01,9.01 | 2026-10-08 |
| 2026-10-08 | SC TO-C | SC TO-C | |
| 2026-08-18 | 4 | FORM 4 | 2026-08-17 |
| 2026-08-17 | 144 | 144 | |
| 2026-08-07 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-08-04 | S-8 | S-8 | |
| 2026-08-04 | 10-Q | 10-Q - PCRX - 06.30.2026 | 2026-06-30 |
| 2026-08-04 | 8-K | 8-K items 2.02,9.01 | 2026-08-04 |
| 2026-06-30 | 8-K | 8-K items 1.01,7.01,9.01 | 2026-06-28 |
| 2026-06-12 | 4 | FORM 4 | 2026-06-10 |
| 2026-06-12 | 4 | FORM 4 | 2026-06-11 |
| 2026-06-12 | 4 | FORM 4 | 2026-06-10 |
| 2026-06-12 | 4 | FORM 4 | 2026-06-10 |
| 2026-06-12 | 4 | FORM 4 | 2026-06-10 |
| 2026-06-12 | 4 | FORM 4 | 2026-06-10 |
| 2026-06-12 | 4 | FORM 4 | 2026-06-10 |
| 2026-06-12 | 4 | FORM 4 | 2026-06-10 |
| 2026-06-12 | 4 | FORM 4 | 2026-06-10 |
| 2026-06-12 | 3 | FORM 3 | 2026-06-09 |
| 2026-06-12 | 144 | 144 |
Forms on file (last 1,000): 4 503, 8-K 161, 144 70, SC 13G/A 52, 10-Q 38, 3 28, DEFA14A 22, CT ORDER 15. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=PCRX (0.002 USD), /gw/filings/filings?ticker=PCRX&form=8-K, /gw/filings/facts?ticker=PCRX&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange